The 51 references in paper A. Smirnov V., A. Rumyantsev SH., А. Смирнов В., А. Румянцев Ш. (2015) “Строение и функции костной ткани в норме и при патологии. Сообщение II // Bone tissue function and structure under normal and pathological condition. Message "” / spz:neicon:nefr:y:2015:i:1:p:8-17

1
Manolagas S.C. Birth And Death Of Bone Cells: basic Regulatory Mechanisms And Implications For The Pathogenesis And Treatment Of Osteoporosis. Endocr Rev. 2000; 21(2): 115-137
(check this in PDF content)
2
Plotkin L.I., Manolagas S.C., Bellido T. Transduction of cell survival signals by connexin-43 hemichannels. J Biol Chem. 2002; 277(10): 8648-8657
(check this in PDF content)
3
Bonewald l.F. Establishment and characterization of an osteocyte- like cell line, MLO-Y4. J Bone Miner Metab. 1999; 17(1): 61-65
(check this in PDF content)
4
Knothe Tate M.L., Adamson J.R., Tami A.E., Bauer T.W. The osteocyte. Int J Biochem Cell Biol. 2004; 36(1): 1-8
(check this in PDF content)
5
Bonewald l.F. Osteocytes: a proposed multifunctional bone cell. J Musculoskelet Neuronal Interact. 2002; 2(3): 239-241
(check this in PDF content)
6
Winkler D.G., Sutherland M.K., Geoghegan J.C. et al. Osteocyte control of bone formation via sclerostin, a novel bmp antagonist. Таблица 2 Основные факторы костного ремоделирования [39] ПоказательСокращенные обозначенияЭффект на костную резорбцию Эффект на костеобразование Примечания В отечеств. литературе В иностр. литературе Цитокины Интерлейкин-1 -6 -11 ИЛ-1 ИЛ-6 ИЛ-11 IL-1 IL-6 IL-11 ↑ ↑ ↑ Активаторы ОК и остеокластогенеза; «провоспалительные» цитокины Фактор некроза опухоли α ФНО-αTNF-α↑Активируют остеокласты Костный морфогенный белок -2 -4 КМБ-2 КМБ-4 ВМР-2 ВМР-4 ↑ ↑ Инициируют остеобластогенез. Относятся к семейству ТФР-β Лейкоз-ингибирующий фактор ЛИФLIF ↑Имеет рецепторы на ОБ. Физиологическое значение
(check this in PDF content)
7
ten Dijke P., Krause C., de Gorter D.J. et al. Osteocyte- derived sclerostin inhibits bone formation: its role in bone morphogenetic protein and Wnt signaling. J Bone Joint Surg Am. 2008; 90 Suppl 1: 31-35
(check this in PDF content)
8
Ubaidus S., Li M., Sultana S. et al. FGF23 is mainly synthesized by osteocytes in the regularly distributed osteocytic lacunar canalicular system established after physiological bone remodeling. J Electron Microsc (Tokyo). 2009; 58(6): 381-392
(check this in PDF content)
9
Clarke B. Normal bone anatomy and physiology. Clin J Am Soc Nephrol. 2008;3 Suppl 3: S131-139
(check this in PDF content)
10
Seeman E., Delmas p.D. Bone guality – the material and structural basis of bone strength and fragility. N Engl J Med. 2006; 354(21): 2250-2261
(check this in PDF content)
11
Robinson J.A., Chatterjee- Kishore M., Yaworsky P.J. et al. Wnt/beta- catenin signaling is a normal physiological response to mechanical loading in bone. J Biol Chem. 2006; 281(42): 3172031728
(check this in PDF content)
12
Fritton S.P., Weinbaum S. Fluid and solute transport in bone: flow- induced mechanotransduction. Annu Rev Fluid Mech. 2009; 41: 347-374
(check this in PDF content)
13
Xing L., Boyce B.F. Reculation of apoptosis in osteoclasts and osteoblastic cells. Biochem Biophys Res Commun. 2005; 328(3): 709-720
(check this in PDF content)
14
Plotkin L.I., Aguirre J.L., Kousteni S. et al. Bisphosphonates and estrogens inhibit osteocyte apoptosis via distinct molecular mechanisms downstream of extracellular signal- regulated kinase activation. J Biol Chem. 2005; 280(8): 7317-7325
(check this in PDF content)
15
Dierkes C., Kreisel M., Schulz A. et al. Catabolic properties of microdissected human endosteal bone lining cells. Calcif Tissue Int. 2009; 84(2): 146-155
(check this in PDF content)
16
Yavropoulou M.P., Yovos J.G. Osteoclastogenesis – current knowledge and future perspectives. J Musculoskelet Neuronal Interact. 2008; 8(3): 204-216
(check this in PDF content)
17
Felix R., Halasy-Nagy J., Wetterwald A. et al. Synthesis of membrane- and matrix- bound colony- stimulating factor-1 by cultured osteoblasts. J Cell Physiol. 1996; 166(2): 311-322
(check this in PDF content)
18
Dai X.M., Ryan G.R., Hapel A.J. et al. Targeted disruption of the mouse colony- stimulating factor 1 receptor gene results in osteopetrosis, mononuclear phagocyte deficiency, increased primitive progenitor cell freguencies, and reproductive defects. Blood. 2002; 99(1): 111-120
(check this in PDF content)
19
Tondravi M.M., Mckercher S.R., Anderson K. et al. Osteopetrosis in mice lacking haematopoietic transcription factor PU.1. Nature. 1997; 386(6620): 81-84
(check this in PDF content)
20
Sharma S.M., Bronisz A., Hu R. et al. MITF and PU.1 recruit p38 MAPK and NFATc1 to target genes during osteoclast differentiation. J Biol Chem. 2007; 282(21): 15921-1599
(check this in PDF content)
21
Yamashita T., Yao Z., Zhang Q. et al. NF-kappa B p50 and p52 regulate receptor activator of NF-kappaB ligand (RANKL) and tumor necrosis factor- induced osteoclast precursor differentiation by activating c-Fos and NFATc1. J Biol Chem. 2007; 282(25): 18245-18253
(check this in PDF content)
22
Kim H., Choi H.K., Shin J.H. et al. Selective inhibition of RANK blocks osteoclast maturation and function and prevents bone loss in mice. J Clin Invest. 2009; 199(4): 813-825
(check this in PDF content)
23
Roodman G.D. pathogenesis of myeloma bone disease. J Cell Biochem. 2010; 109(2): 283-291
(check this in PDF content)
24
Gluliani N., Colla S., Rizzoli V. Update on the pathogenesis of osteolysis in multiple myeloma patients. Acta Biomed. 2004; 75(3): 143-152
(check this in PDF content)
25
Li J., Sarosi I., Yan X.Q. et al. RANK is the intrinsic hematopoietic cell surface receptor that controls osteoclastogenesis and regulation of bone mass and calcium metabolism. Proc Natl Acad Sci USA. 2000; 97(4): 1566-1571
(check this in PDF content)
26
Charopoulos I., Orme S., Giannoudis P.V. The role and efficacy of denosumab in the treatment of osteoporosis: an update. expert opin drug Saf. 2011; 10(2):205-17
(check this in PDF content)
27
Gillespie M.T. impact of cytokines and t lymphocytes upon osteoclast differentiation and function. Arthritis Res Ther. 2007; 9(2): 103
(check this in PDF content)
28
Tolar J., Teitelbaum S.L., Orchard P.J. Osteopetrosis. N Engl J Med. 2004; 351 (27): 2839-2849
(check this in PDF content)
29
Teitelbaum S.L. Osteoclasts: what do they do and how do they do it? Am J Pathol. 2007; 170(2): 427-435
(check this in PDF content)
30
Ross F.P., Teitelbaum S.L. Alphavbeta3 and macrophage colony- stimulating factor: partners in osteoclast biology. Immunol Rev. 2005; 208: 88-105
(check this in PDF content)
31
Blair H.C., Zaidi M., Schlesinger P.H. Mechanisms balancing skeletal matrix synthesis and degradation. Biochem J. 2002; 364(Pt 2): 329-341
(check this in PDF content)
32
Burstone M.S. Histochemical demonstration of acid phosphatase activity in osteoclasts. J Histochem Cytochem. 1959; 7(1): 39-41
(check this in PDF content)
33
Seibel M.J. Biochemical markers of bone turnover: Part I: Biochemistry and variability. Clin Biochem Rev. 2005; 26(4): 97-122
(check this in PDF content)
34
Ek-Rylander B., Flores M., Wendel M. et al. Dephosphorylation of osteopontin and bone sialoprotein by osteoclastic tartrateresistant acid phosphatese. modulation of osteoclast adhesion in vitro. J Biol Chem. 1994; 269(21): 14853-14856
(check this in PDF content)
35
Murphy M.G., Cerchio K., Stoch S.A. et al. Effect of L-000845704, an alpha vbeta3 integrin antagonist, on markers of bone turnover and bone mineral density in postmenopausal osteoporotic women. J Clin Endocrinol Metab. 2005; 90(4): 2022-2028
(check this in PDF content)
36
Pérez-Castrillón J.L., Pinacho F., De Luis D. et al. Odanacatib, a new drug for the treatment of osteoporosis: review of the results in postmenopausal women. J osteoporos. 2010; 2010.pii: 401581
(check this in PDF content)
37
Денисов-Никольский Ю.И., Докторов А.А., Матвейчук И.В. Структура и функция костной ткани в норме: в кн.: Руководство по остеопорозу. Под ред. Л.И.Беневоленской.- М.: БИНОМ. Лаборатория знаний. 2003; 524 с- гл. 2, с.56-76 [Denisov-nikol`skii` Iu.I., Doktorov A.A., Matvei`chuk I.V. Struktura i funktciia kostnoi` tkani v norme: v kn.: Rukovodstvo po osteoporozu. Pod red. L.I.Benevolenskoi`.- M.: BINOM. LABORATORIIA ZNANII`. 2003; 524 S- GL. 2, S.56-76]
(check this in PDF content)
38
Hadjidakis D.J., Androulakis I.I. Bone remodeling. Ann N Y Acad Sci. 2006; 1092: 385-396
(check this in PDF content)
39
Беневоленская Л.И., Насонов Е.А. Патогенез остеопороза: в кн.: Руководство по остеопорозу. Под ред. Л.И.Беневоленской.- М.: БИНОМ. Лаборатория знаний. 2003; – 524 с- гл. 3, с.77-104 [Benevolenskaia L.I., Nasonov E.A. patogenez osteoporoza: V kn.: Rukovodstvo po osteoporozu. Pod red. L.I.Benevolenskoi`.- M.: BINOM. LABORATORIIA ZNANII`. 2003; – 524 S- GL. 3, S.77-104]
(check this in PDF content)
40
Котельников Г.П., Булгакова С.В. Остеопороз: руководство. М.: ГЭОТАР- Медиа. 2010; 512 с [Kotel`nikov G.P., Bulgakova S.V. Osteoporoz: rukovodstvo. M.: GEOTAR- MEDIA. 2010; 512 S]
(check this in PDF content)
41
Hauge E.M., Qvesel D., Eriksen E.F. et al. Cancellous bone remodeling occurs in specialized compartments lined by cells expressing osteoblastic markers. J Bone Miner Res. 2001; 16(9): 1575-1582
(check this in PDF content)
42
Eriksen E.F., Eghbali- Fatourechi G.Z., Khosla S. Remodeling and vascular spaces in bone. J Bone Miner Res. 2007; 22(1): 1-6
(check this in PDF content)
43
Khosla S., Westendorf J.J., Oursler M.J. Building bone to reverse osteoporosis and repair fractures. J Clin Invest. 2008; 118(2): 421-428
(check this in PDF content)
44
Mohan S., Baylink D.J. Insulin- like growth factor system components and the coupling of bone formation to resorption. Horm Res. 1996; 45 Suppl 1: 59-62
(check this in PDF content)
45
Bonewald L.F., Mundy G.R. Role of transforming growth factor- beta in bone remodeling. Clin Orthop Relat Res. 1990; (250): 261-276
(check this in PDF content)
46
Zhao C., Irie N., Takada Y. et al. Bidirectional Ephrin B2-Eph B4 signaling controls bone homeostasis. Cell Metab. 2006; 4(2): 111-121
(check this in PDF content)
47
Matsuo K., Irie N. Osteoclast- osteoblast communication. Arch Biochem Biophys. 2008; 473(2): 201-209
(check this in PDF content)
48
Ryu J., Kim H.J., Chang E.J. et al. Sphingosine 1-phosphate as a regulator of osteoclast differentiation and osteoclast- osteoblast coupling. Embo J. 2006; 25(24): 5840-5851
(check this in PDF content)
49
Irie N., Takada Y., Watanabe Y. et al. Bidirectional signaling through ephrin A2- Eph A2 enhances osteoclastogenesis and suppresses osteoblastogenesis. J Biol Chem. 2009; 284(21): 14637-14644
(check this in PDF content)
50
Martin T.J., Allan E.H., Ho P.W. et al. Communication between Ephrin B2 and Eph B4 within the osteoblast lineage. Adv Exp Med Biol. 2010; 658: 51-60
(check this in PDF content)
51
Martin T.J., Gooi J.H., Sims N.F. Molecular mechanisms in coupling of bone formation to resorption. Crit Rev Eukaryot Gene Expr. 2009; 19(1): 73-88 Авторы заявляют об отсутствии конфликта интересов.
(check this in PDF content)